{'fraction_non_alphanumeric': 0.02967359050445104, 'fraction_numerical': 0.00741839762611276, 'mean_word_length': 5.308411214953271, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A76: Long‐Term Efficacy of Canakinumab in Childhood Colchicine Resistant Familial Mediterranean Fever

Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory syndrome. FMF is caused by mutations in the MEFV gene which encodes the pyrin protein, that has an important role in the activation of IL‐1β. Evidence from case reports/series and one controlled study supports IL‐1 blockage as a potential treatment for FMF. Canakinumab (CAN) is a selective fully human monoclonal anti‐IL‐1β antibody. This study served as a proof of concept to evaluate the role of CAN in the treatment of pediatric colchicine resistant (CR)‐FMF with a longterm extension.